Merrimack Pharmaceuticals, Inc (MACK)
$14.73
+0.02
(+0.14%)▲
Insights on Merrimack Pharmaceuticals, Inc
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 52.9% return, outperforming this stock by 31.8%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 240.5% return, outperforming this stock by 145.1%
Performance
- $14.71$14.75$14.73
0.17%
Downside
Day's Volatility :0.31%
Upside
0.14%
- $11.53$15.89$14.73
21.72%
Downside
52 Weeks Volatility :27.44%
Upside
7.3%
Returns
| Period | Merrimack Pharmaceuticals, Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 10.6% | 1.1% | 0.0% |
6 Months | 19.98% | 12.5% | 0.0% |
1 Year | 21.57% | 6.9% | 2.2% |
3 Years | 95.35% | 14.3% | -23.0% |
Highlights
Market Capitalization | 214.0M |
Book Value | $1.31 |
Earnings Per Share (EPS) | -0.08 |
PEG Ratio | 0.07 |
Wall Street Target Price | 4.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -6.97% |
Return On Equity TTM | -6.22% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | -9.1M |
EBITDA | -2.8M |
Diluted Eps TTM | -0.08 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Downside of 72.84%
Technicals Summary
Sell
Neutral
Buy
Merrimack Pharmaceuticals, Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Merrimack Pharmaceuticals, Inc | -0.14% | 19.98% | 21.57% | 95.35% | 170.75% |
 Moderna, Inc. | 1.34% | 41.81% | -16.73% | -38.71% | 314.51% |
 Regeneron Pharmaceuticals, Inc. | -5.68% | 13.74% | 14.81% | 80.88% | 159.02% |
 Novo Nordisk A/s | -2.24% | 29.49% | 49.67% | 240.51% | 421.0% |
 Vertex Pharmaceuticals Incorporated | -4.23% | 10.39% | 23.96% | 84.71% | 131.85% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Merrimack Pharmaceuticals, Inc | NA | NA | 0.07 | 0.0 | -0.06 | -0.07 | NA | 1.31 |
Moderna, Inc. | 24.73 | NA | 0.0 | -6.77 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 26.13 | 26.13 | 1.46 | 45.02 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 48.36 | 48.36 | 2.4 | 3.34 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 29.17 | 29.17 | 0.53 | 16.75 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Merrimack Pharmaceuticals, Inc | Sell | $214.0M | 170.75% | NA | 0.0% |
Moderna, Inc. | Buy | $41.3B | 314.51% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $99.6B | 159.02% | 26.13 | 30.14% |
Novo Nordisk A/s | Buy | $573.9B | 421.0% | 48.36 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $104.7B | 131.85% | 29.17 | 36.68% |
Institutional Holdings
Western Standard LLC
14.95%Newtyn Management LLC
12.89%BlackRock Inc
5.12%Vanguard Group Inc
4.19%Madison Avenue Partners, LP
3.81%ADAR1 Capital Management LLC
3.78%
Company Information
merrimack is a fully integrated biopharmaceutical company that views cancer as a complex engineering challenge. through systems biology, which brings together the fields of biology, computing and engineering, merrimack aims to decrease uncertainty in drug development and clinical validation, and move discovery efforts beyond trial and error. such an approach has the potential to make individualized treatment of patients a reality. merrimack's first commercial product, onivydetm (irinotecan liposome injection), was approved by the u.s. fda on october 22, 2015. with four additional candidates in clinical studies, several in preclinical development and multiple biomarkers designed to support patient selection, merrimack is building one of the most robust oncology pipelines in the industry. for more information, please visit merrimack's website at www.merrimack.com or connect on twitter at @merrimackpharma.
Organization | Merrimack Pharmaceuticals, Inc |
Employees | 0 |
CEO | Mr. Gary L. Crocker M.B.A. |
Industry | Health Technology |
